secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071474
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q1 net loss $57.5M ($1.09/shr), cash $138.9M; pipeline on track for 2026 data
--------------------------------------------------------------------------------

- Net loss $57.5M ($1.09/shr) vs $43.0M ($0.82) in Q1 2024; non-cash stock comp $15.9M.
- Cash and cash equivalents $138.9M; company believes current cash funds operations into 2026.
- R&D expenses $43.6M, up from $29.9M YoY, driven by increased clinical and manufacturing activities.
- Phase 3 GLOW2 (DR), DAYBREAK (wet AMD) for tarcocimab and KSI-501; Phase 1b APEX data for KSI-101 expected.
- Investor R&D Update scheduled for July 16, 2025; topline data targeted in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017025071474/0000950170-25-071474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017025071474/kod-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer